Experts are increasingly investigating retatrutide, a novel treatment created by Eli Lilly, as a significant breakthrough in body management. Unlike many existing approaches, retatrutide is a double -action receptor targeting equally GLP-1 and GIP, chemicals that influence satiety and glucose co